These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 28832225)

  • 1. MUC1 aptamer-conjugated mesoporous silica nanoparticles effectively target breast cancer cells.
    Hanafi-Bojd MY; Moosavian Kalat SA; Taghdisi SM; Ansari L; Abnous K; Malaekeh-Nikouei B
    Drug Dev Ind Pharm; 2018 Jan; 44(1):13-18. PubMed ID: 28832225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
    Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B
    Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
    Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
    Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced theranostic efficacy of epirubicin-loaded SPION@MSN through co-delivery of an anti-miR-21-expressing plasmid and ZIF-8 hybridization to target colon adenocarcinoma.
    Abrishami A; Bahrami AR; Saljooghi AS; Matin MM
    Nanoscale; 2024 Mar; 16(12):6215-6240. PubMed ID: 38446130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
    Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
    Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo.
    Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM
    Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smart aptamer-modified calcium carbonate nanoparticles for controlled release and targeted delivery of epirubicin and melittin into cancer cells in vitro and in vivo.
    Yazdian-Robati R; Arab A; Ramezani M; Rafatpanah H; Bahreyni A; Nabavinia MS; Abnous K; Taghdisi SM
    Drug Dev Ind Pharm; 2019 Apr; 45(4):603-610. PubMed ID: 30633594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled release of silyl ether camptothecin from thiol-ene click chemistry-functionalized mesoporous silica nanoparticles.
    Yan Y; Fu J; Wang T; Lu X
    Acta Biomater; 2017 Mar; 51():471-478. PubMed ID: 28131940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
    Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
    Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeted delivery and controlled release of doxorubicin to cancer cells by smart ATP-responsive Y-shaped DNA structure-capped mesoporous silica nanoparticles.
    Bagheri E; Alibolandi M; Abnous K; Taghdisi SM; Ramezani M
    J Mater Chem B; 2021 Feb; 9(5):1351-1363. PubMed ID: 33447840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aptamer-modified chitosan-capped mesoporous silica nanoparticles for co-delivery of cytarabine and daunorubicin in leukemia.
    Heydari SR; Ghahremani MH; Atyabi F; Bafkary R; Jaafari MR; Dinarvand R
    Int J Pharm; 2023 Nov; 646():123495. PubMed ID: 37806507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo.
    Taghdisi SM; Danesh NM; Ramezani M; Lavaee P; Jalalian SH; Robati RY; Abnous K
    Eur J Pharm Biopharm; 2016 May; 102():152-8. PubMed ID: 26987703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Delivery of Epirubicin to Cancer Cells by Polyvalent Aptamer System in vitro and in vivo.
    Yazdian-Robati R; Ramezani M; Jalalian SH; Abnous K; Taghdisi SM
    Pharm Res; 2016 Sep; 33(9):2289-97. PubMed ID: 27283831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-targeted delivery system using hollow silica nanoparticles with H
    Mirzaei S; Khademi Z; Zolfaghari R; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
    Drug Dev Ind Pharm; 2023 Oct; 49(10):648-657. PubMed ID: 37772892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery.
    Taghavi S; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
    Cancer Lett; 2017 Aug; 400():1-8. PubMed ID: 28412238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7.
    Gandhi R; Khatri N; Baradia D; Vhora I; Misra A
    Drug Deliv; 2016 May; 23(4):1152-62. PubMed ID: 25586675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smart delivery of epirubicin to cancer cells using aptamer-modified ferritin nanoparticles.
    Yazdian-Robati R; Bayat P; Dehestani S; Hashemi M; Taghdisi SM; Abnous K
    J Drug Target; 2022 Jun; 30(5):567-576. PubMed ID: 34991424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thermo-responsive mesoporous silica/lipid bilayer hybrid nanoparticles for doxorubicin on-demand delivery and reduced premature release.
    Zhang Q; Chen X; Shi H; Dong G; Zhou M; Wang T; Xin H
    Colloids Surf B Biointerfaces; 2017 Dec; 160():527-534. PubMed ID: 29024917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified mesoporous silica nanoparticles for enhancing oral bioavailability and antihypertensive activity of poorly water soluble valsartan.
    Biswas N
    Eur J Pharm Sci; 2017 Mar; 99():152-160. PubMed ID: 27993684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. pH responsive cylindrical MSN for oral delivery of insulin-design, fabrication and evaluation.
    Guha A; Biswas N; Bhattacharjee K; Sahoo N; Kuotsu K
    Drug Deliv; 2016 Nov; 23(9):3552-3561. PubMed ID: 27540687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.